Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASCO: BeiGene, Novartis Herald Global PD-1 Contender In ESCC

Filings Approaching

Executive Summary

The Chinese biotech is set to extend the reach of its PD-1 candidate to the global market with a second major clinical win and following an earlier major deal with Novartis.

You may also be interested in...



BeiGene’s PD-1 Remains Solid In First Global Pivotal Study

Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.

China's CARsgen Raises $400m In Third-Largest Biotech IPO This Year

Chinese CAR-T therapy developer raises new funds to progress pipeline in over-subscribed IPO which ranks as the third-largest globally in the biotech sector to date this year.

'We Must Innovate': US Biotechs Chart New Growth Path In China

Facing a increasingly competitive environment and tense bilateral relationship, US biotechs must innovate and differentiate while protecting their innovations in China, say panelists at the BIO annual conference.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel